Sofía Alejandra Galvis Garrido
Research Subjects
Sofía Alejandra Galvis Garrido has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Sebastian Zamora Gutierrez
Instituto Tecnologico y de Estudios Superiores de Monterrey
1 shared publication - Hannia Bertha Matt Hernandez
Allergy and Clinical Immunology, Hospital Christus Muguerza Reynosa, Reynosa 88610, Mexico
1 shared publication - Madelayne Cecilia Enriquez Cobos
Universidad de Guayaquil
1 shared publication - Mónica Alexandra Caiza Asitimbay
Universidad Nacional de Chimborazo, Breve descripción: Médico General, Especialista en Reumatología y Medicina Legal. Docente Investigador, Riobamba - Ecuador
1 shared publication
Latest Publications
- Open Access
- 30 April 2026
- Published by Sapienza: International Journal of Interdisciplinary Studies in Sapienza: International Journal of Interdisciplinary Studies
- Vol. 7 (2) , e26010
Intratympanic vs systemic steroids for sudden sensorineural hearing loss: a systematic review of recovery
Background: Idiopathic sudden sensorineural hearing loss (ISSNHL) is an otologic emergency with an incidence of 5–27 per 100,000 persons per year. The primary treatment method is corticosteroids, although the most effective way of administration is a controversial issue. The aim of the study is to compare the results of hearing recovery in intratympanic and systemic corticosteroid in ISSNHL. Methods: We used PRISMA to systematically search PubMed, Scopus and Web of Science (2015–2025) to identify randomized controlled trials and prospective comparative studies. The extraction of data was done on the improvement of pure-tone averages, recovery rates and complications. Cochrane RoB 2 was used to assess the risk of bias. Findings: The number of studies and patients included was 17 and 1,649 respectively. In most studies, recovery rates ranged from 60% to 70% across studies. The largest RCT with a 67.3% efficacy rate versus 57.4% with systemic alone (n=47) was combined systemic-intratympanic therapy (n=156) (p>0.05). Salvage intratympanic therapy (n=43) yielded a mean hearing gain of 13.6 dB as compared to no improvement with observation (n=48). Such prognostic variables as vertigo (p=0.039), cardiovascular comorbidity (p=0.02) and initial severity of hearing loss (p=0.033) had a significant impact. Conclusions: Intratympanic corticosteroids have the same efficacy as systemic therapy in the treatment of primary ISSNHL and have positive safety profiles. Severe cases may be helped by combined therapy. In case of a failed systemic treatment, salvage intratympanic therapy works.
- 30 April 2026
- Published by Sapienza: International Journal of Interdisciplinary Studies in Sapienza: International Journal of Interdisciplinary Studies
- Vol. 7 (2) , e26010
Open AccessIntratympanic vs systemic steroids for sudden sensorineural hearing loss: a systematic review of recovery
Background: Idiopathic sudden sensorineural hearing loss (ISSNHL) is an otologic emergency with an incidence of 5–27 per 100,000 persons per year. The primary treatment method is corticosteroids, although the most effective way of administration is a controversial issue. The aim of the study is to compare the results of hearing recovery in intratympanic and systemic corticosteroid in ISSNHL. Methods: We used PRISMA to systematically search PubMed, Scopus and Web of Science (2015–2025) to identify randomized controlled trials and prospective comparative studies. The extraction of data was done on the improvement of pure-tone averages, recovery rates and complications. Cochrane RoB 2 was used to assess the risk of bias. Findings: The number of studies and patients included was 17 and 1,649 respectively. In most studies, recovery rates ranged from 60% to 70% across studies. The largest RCT with a 67.3% efficacy rate versus 57.4% with systemic alone (n=47) was combined systemic-intratympanic therapy (n=156) (p>0.05). Salvage intratympanic therapy (n=43) yielded a mean hearing gain of 13.6 dB as compared to no improvement with observation (n=48). Such prognostic variables as vertigo (p=0.039), cardiovascular comorbidity (p=0.02) and initial severity of hearing loss (p=0.033) had a significant impact. Conclusions: Intratympanic corticosteroids have the same efficacy as systemic therapy in the treatment of primary ISSNHL and have positive safety profiles. Severe cases may be helped by combined therapy. In case of a failed systemic treatment, salvage intratympanic therapy works.